New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2014
08:57 EDTHEBHemispherx to present results to date of Ampligen/FluMist trial
Hemispherx Biopharma announced that the ASM Biodefense Meeting is scheduled for January 27-29 in Washington DC. The University of Alabama and Hemispherx's poster presentation is entitled "Seasonal Influenza Vaccine and a TLR-3 Agonist, Rintatolimod (Ampligen), Given Intranasally Produced Cross-Reactive IgA Antibodies Against Pathogenic H5N1 Influenza HA" and will be provided in poster format by Dr. E. Turner Overton, an infectious disease expert at UAB, in the afternoon of January 29. Representatives of Hemispherx Biopharma and Prof. Overton, the principal researcher conducting the clinical trial at the University of Alabama at Birmingham, will describe the results to date of the Ampligen/FluMist intranasal influenza vaccine clinical trial and address questions during a media conference at the National Press Club in Washington, DC scheduled on Thursday, January 30.
News For HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
09:27 EDTHEBHemispherx says Ampligen blocks certain Ebola Viral Disease protein
Hemispherx Biopharma announced that it had received a new research report from Professor Tramontano in the Department of Life and Environmental Sciences, University of Cagliari, Italy. The biochemical study demonstrates Ampligen can successfully bind to the lethal EVD viral protein designated VP35. Experiments being conducted establish the scientific foundation for Ampligen, an experimental drug, as a potential preventive and early onset therapeutic for Ebola, the company said.
November 10, 2014
08:48 EDTHEBHemispherx reports Q3 EPS (2c), one estimate (3c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use